Literature DB >> 12769669

Regulation of UDP glucuronosyltransferase genes.

P I Mackenzie1, P A Gregory, D A Gardner-Stephen, R H Lewinsky, B R Jorgensen, T Nishiyama, Wen Xie, A Radominska-Pandya.   

Abstract

The UDP glucuronosyltransferase (UGT) content of cells and tissues is a major determinant of our response to those chemicals that are primarily eliminated by conjugation with glucuronic acid. There are marked interindividual differences in the content of UGTs in the liver and other organs. The mechanisms that lead to these differences are unknown but are most likely the result of differential UGT gene expression. Several transcription factors involved in the regulation of UGT genes have been identified. These include factors such as Hepatocyte Nuclear Factor 1, CAAT-Enhancer Binding Protein, Octamer transcription Factor 1 and Pbx2, which appear to control the constitutive levels of UGTs in tissues and organs. In addition, UGT gene expression is also modulated by hormones, drugs and other foreign chemicals through the action of proteins that bind and/or sense the presence of these chemicals. These proteins include the Ah receptor, members of the nuclear receptor superfamily, such as CAR and PXR and transcription factors that respond to stress.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12769669     DOI: 10.2174/1389200033489442

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  18 in total

Review 1.  Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR.

Authors:  Antonia H Tolson; Hongbing Wang
Journal:  Adv Drug Deliv Rev       Date:  2010-08-17       Impact factor: 15.470

Review 2.  Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds.

Authors:  E J Reschly; Matthew D Krasowski
Journal:  Curr Drug Metab       Date:  2006-05       Impact factor: 3.731

Review 3.  First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.

Authors:  Baojian Wu; Kaustubh Kulkarni; Sumit Basu; Shuxing Zhang; Ming Hu
Journal:  J Pharm Sci       Date:  2011-04-11       Impact factor: 3.534

Review 4.  Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.

Authors:  Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Induction of mouse UDP-glucuronosyltransferase mRNA expression in liver and intestine by activators of aryl-hydrocarbon receptor, constitutive androstane receptor, pregnane X receptor, peroxisome proliferator-activated receptor alpha, and nuclear factor erythroid 2-related factor 2.

Authors:  David B Buckley; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2009-01-14       Impact factor: 3.922

6.  Metabolomics reveals a novel vitamin E metabolite and attenuated vitamin E metabolism upon PXR activation.

Authors:  Joo-Youn Cho; Dong Wook Kang; Xiaochao Ma; Sung-Hoon Ahn; Kristopher W Krausz; Hans Luecke; Jeffrey R Idle; Frank J Gonzalez
Journal:  J Lipid Res       Date:  2009-01-13       Impact factor: 5.922

Review 7.  The pregnane X receptor: from bench to bedside.

Authors:  Xiaochao Ma; Jeffrey R Idle; Frank J Gonzalez
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-07       Impact factor: 4.481

Review 8.  ABC of oral bioavailability: transporters as gatekeepers in the gut.

Authors:  C G Dietrich; A Geier; R P J Oude Elferink
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

9.  Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver.

Authors:  Wanqing Liu; Jacqueline Ramírez; Eric R Gamazon; Snezana Mirkov; Peixian Chen; Kehua Wu; Chang Sun; Nancy J Cox; Edwin Cook; Soma Das; Mark J Ratain
Journal:  Hum Mol Genet       Date:  2014-05-30       Impact factor: 6.150

10.  Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells.

Authors:  Anne-Sophie Bélanger; Jelena Tojcic; Mario Harvey; Chantal Guillemette
Journal:  BMC Mol Biol       Date:  2010-01-22       Impact factor: 2.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.